

Report Information

More information from: <https://www.marketresearchfuture.com/reports/immortalized-cell-line-market-751>

Immortalized Cell Line Market Research Report - Global Forecast till 2030

Report / Search Code: MRFR/LS/0267-CR

Publish Date: August, 2019

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------------

Description:

The Immortalized Cell Line Market is expected to reach USD 2601.83 Million by 2030 at 4.90% CAGR during the forecast period 2022-2030. Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. These cell lines are expected to grow due to the rise in vaccine production and innovative technologies.


Besides, the ability of cell line culture to provide more physiologically relevant information and more accurate data in-vitro tests has led cell line culture systems to become acceptable in comparison to media culture.

The increasing application in biotech and pharmaceutical companies and hospitals, a growing number of patients in need of organ transplantation, and the rise in the patient population affected by cancer are the major drivers propelling market growth. However, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination may hinder the growth of the market.

Market Dynamics

The increasing demand for organ donation due to scarcity in the availability of organs is driving the need for artificially created biological cells. For instance, according to the US Department of Health & Human Services Organ Procurement and Transplantation Network (OPTN), as of November 2016, 121,678 patients were waiting for a life-saving organ transplant. This rising demand for an organ transplant is expected to drive the growth of the market during the forecast period. Additionally, increasing application in biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer are likely to support market growth. On the other hand, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination is anticipated to hamper the market growth.

Immortalized Cell Line Market Size, by End User, 2017 (USD Million)



Source: MRFR Analysis

Segmentation

The immortalized cell line market has been segmented into method, application, and end user.

Based on the method, the global market has been segmented into virus induction, hTERT expression, inactivation of tumor suppression genes, and others. The virus induction segment is further divided into EBV genes, SV40 T antigen, HPV-16 E6/6 gene, and others. The hTERT expression segment is sub-segmented into P53 and Myc T58A.

The immortalized cell line market, based on application, is segmented into diagnostics, drug discovery, vaccine production, tissue engineering and regenerative medicine, and others.


Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017.

Key Players

The prominent players in the immortalized cell line market are **Thermo Fisher Scientific (US)**, **ATCC (American Type Culture Collection Inc.) (US)**, **Valneva (France)**, **Sartorius AG (Germany)**, **Lonza Group, AG (Switzerland)**, **Merck KGaA (Germany)**, **Selexis SA (Switzerland)**, **WuXi App Tec (China)**, **European Collection of Authenticated Cell Cultures (ECACC) (Europe)**, and **Corning Incorporated (US)**

Some of the key strategies followed by the players operating in the immortalized cell line market are innovation, product development, acquisition, and expansion.

Immortalized Cell Line Market Share, by Region, 2017 (%)



Source: MRFR Analysis

Regional Analysis

The immortalized cell line market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is estimated to dominate the immortalized cell line market during the forecast period. This is attributed to an increase in the occurrence of cancer, the presence of well-established pharmaceutical and biotechnology industry, increasing awareness of immortalized cell lines, and strong research funding.

The European market for immortalized cell line is expected to be the second-largest during the forecast period. Increasing government support, well-developed technology, and rising cases of cancer are expected to boost the growth of the market in this region.

Asia-Pacific is estimated to be the fastest-growing market due to the increasing expenditure on healthcare by government and private sector companies. Moreover, the growing awareness about healthcare and large untapped patient population have led to the increased focus of key players on expansion in this region. Furthermore, the region accounted for a market share of 17.8% in 2017.

The immortalized cell line market in the Middle East & Africa is expected to hold the least market share.

Key Updates

- In April 2018, Lonza Group, AG announced the opening of the world's largest dedicated cell-and-gene-therapy manufacturing facility in Pearland, Greater Houston, TX (US). The manufacturing site was built in anticipation of the rising demand from developers of cell and gene therapies.
- In August 2017, Thermo Fisher Scientific acquired Patheon for 7.2 USD million. Patheon's CDMO services are likely to complement Thermo Fisher Scientific's life sciences technologies designed to support research, clinical trials, and production.

Market Segmentation

Immortalized Cell Line Market, by Method

- Virus Induction
 - EBV genes
 - SV40 T antigen

- HPV-16 E6/6 gene
 - Others
- HTERT Expression
 - P53
 - Myc T58A
- Inactivation of Tumour Suppression Genes
- Others

Immortalized Cell Line Market, by Application

- Diagnostics
- Drug Discovery
- Vaccine Production
- Tissue Engineering and Regenerative Medicines
- Others

Immortalized Cell Line Market, by End User

- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Research Laboratories

Immortalized Cell Line Market, by Region

- Americas
 - North America
 - US
 - Canada
 - South America
- Europe
 - Western Europe
 - Germany
 - UK
 - France
 - Italy
 - Spain
 - Rest of Western Europe
 - Eastern Europe
- Asia-Pacific

- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific

- Middle East & Africa

- Middle East
- Africa

Intended Audience

- Research and development (R&D) companies
- Government research institutes
- Academic institutes and universities

Table of Content:

Contents	
1 Report Prologue	
2 Executive Summary	
3 Market Introduction	
3.1 Scope of Study	19
3.2 Research Objective	19
3.3 List of Assumptions	19
3.4 Market Structure	20
4 Research Methodology	
4.1 Research Process	22
4.2 Primary Research	23
4.3 Secondary Research	24
4.4 Market Size Estimation	25
4.5 Forecast Model	25
5 Market Dynamics	
5.1 Introduction	27
5.2 Drivers	28
5.2.1 Increasing Application in Biotech & Pharmaceutical Companies and Hospitals	28
5.2.2 Growing Number of Patients in Need of Organ Transplantation	28
5.2.3 Rise in the Patient Population Affected by Cancer	29
5.3 Restraints	29
5.3.1 High Cost of Equipment	29
5.3.2 Developing Stable and Authentic Cell Lines	29
5.4 Opportunities	30
5.4.1 Entering Untapped Markets	30
5.4.2 Increasing Use of cell Line Culture in Cancer and Stem Cell Research	30
6 Market Factor Analysis	
6.1 Porters Five Forces Analysis	32
6.1.1 Bargaining Power of Suppliers	32
6.1.2 Bargaining Power of Buyers	32
6.1.3 Threat of New Entrants	32
6.1.4 Threat of Substitutes	33
6.1.5 Intensity of Rivalry	33
6.2 Supply Chain Analysis	33
6.2.1 R&D	33
6.2.2 Manufacturing	33
6.2.3 Distribution & Sales	34
6.2.4 Post-Sales Monitoring	34
6.3 Investment Opportunities	34
6.4 Pricing Analysis	34
7 Immortalized Cell Line Market, by Method	
7.1 Overview	36
7.1.1 Virus Induction	38
7.1.2 HTERT Expression	39
7.1.3 Inactivation of Tumour Suppression Genes	40
7.1.4 Others	40
8 Immortalized Cell Line Market, by Application	
8.1 Overview	42
8.1.1 Diagnostics	43
8.1.2 Drug Discovery	43

8.1.3 Vaccine Production	44
8.1.4 Tissue Engineering and Regenerative Medicines	45
8.1.5 Others	45
9 Immortalized Cell Line Market, by End-user	
9.1 Overview	47
9.1.1 Introduction	47
9.1.2 Pharmaceutical and Biopharmaceutical Companies	48
9.1.3 Contract Research Organizations	48
9.1.4 Research Laboratories	49
10 Global Immortalized Cell Line Market, By Region	
10.1 Overview	51
10.2 Americas	52
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.2.1 North America	54
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.2.1.1 US	57
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.2.1.2 Canada	58
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.2.2 South America	60
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3 Europe	62
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3.1 Western Europe	65
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3.1.1 Germany	67
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3.1.2 France	69
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3.1.3 UK	71
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3.1.4 Italy	73
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3.1.5 Spain	75
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3.1.6 Rest of Western Europe	76
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.3.2 Eastern Europe	78
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.4 Asia-Pacific	80
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.4.1 Japan	82
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.4.2 China	84
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.4.3 India	86
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.4.4 South Korea	87
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.4.5 Rest of Asia-Pacific	89
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.5 Middle East and Africa	91
Immortalized Cell Line Market, by Method	

Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.5.1 Middle East 93	
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
10.5.2 Africa 95	
Immortalized Cell Line Market, by Method	
Immortalized Cell Line Market, by Application	
Immortalized Cell Line Market, by End-user	
11 Competitive Landscape	
11.1 Company Market Share Analysis 98	
11.1.1 Introduction 98	
11.2 Competitive Landscape 99	
11.2.1 Introduction 99	
11.3 Key Developments 100	
12 Company Profiles	
12.1 Thermo Fisher Scientific 102	
12.1.1 Company Overview 102	
12.1.2 Financial Overview 102	
12.1.3 Products Offered 103	
12.1.4 Key Developments 103	
12.1.5 SWOT Analysis 103	
12.1.6 Key Strategies 104	
12.2 ATCC (American Type Culture Collection Inc.) 105	
12.2.1 Company Overview 105	
12.2.2 Financial Overview 105	
12.2.3 Products Offered 105	
12.2.4 Key Developments 106	
12.2.5 SWOT Analysis 107	
12.2.6 Key Strategies 107	
12.3 Valneva 108	
12.3.1 Company Overview 108	
12.3.2 Financial Overview 108	
12.3.3 Products Offered 108	
12.3.4 1.3.4 Key Developments 109	
12.3.5 SWOT Analysis 109	
12.3.6 Key Strategies 109	
12.4 Sartorius AG 110	
12.4.1 Company Overview 110	
12.4.2 Financial Overview 110	
12.4.3 Products Offered 111	
12.4.4 Key Developments 111	
12.4.5 SWOT Analysis 111	
12.4.6 Key Strategies 111	
12.5 Lonza Group, AG 112	
12.5.1 Company Overview 112	
12.5.2 Financial Overview 112	
12.5.3 Products Offered 112	
12.5.4 Key Developments 113	
12.5.5 Swot Analysis 113	
12.5.6 Key Strategies 113	
12.6 Merck KGaA 114	
12.6.1 Company Overview 114	
12.6.2 Financial Overview 114	
12.6.3 Products Offered 115	
12.6.4 Key Developments 115	
12.6.5 SWOT Analysis 115	
12.6.6 Key Strategies 115	
12.7 Selexis SA 116	
12.7.1 Company Overview 116	
12.7.2 Financial Overview 116	
12.7.3 Products Offered 116	
12.7.4 Key Developments 116	
12.7.5 SWOT Analysis 117	
12.7.6 Key Strategies 117	
12.8 Wuxi App Tec 118	
12.8.1 Company Overview 118	
12.8.2 Financial Overview 118	
12.8.3 Products Offered 119	
12.8.4 Key Developments 119	
12.8.5 SWOT Analysis 119	
12.8.6 Key Strategies 119	
12.9 European Collection of Authenticated Cell Cultures (ECACC) 120	
12.9.1 Company Overview 120	
12.9.2 Financial Overview 120	
12.9.3 Products Offered 120	
12.9.4 Key Developments 120	
12.9.5 SWOT Analysis 121	
12.9.6 Key Strategies 121	
12.10 Corning Incorporated 122	
12.10.1 Company Overview 122	
12.10.2 Financial Overview 122	
12.10.3 Products Offered 123	
12.10.4 Key Developments 123	
12.10.5 SWOT Analysis 123	
12.10.6 Key Strategies 123	
13 Appendix	
13.1 Discussion Blue Print 125	
14 List of Tables	
TABLE 1 MARKET SYNOPSIS 17	
TABLE 2 LIST OF ASSUMPTIONS 19	
TABLE 3 GLOBAL IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 36	

TABLE 4 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	37
TABLE 5 GLOBAL IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION)	37
TABLE 6 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY REGION 2020–2027 (USD MILLION)	38
TABLE 7 GLOBAL IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY REGION 2020–2027 (USD MILLION)	39
TABLE 8 GLOBAL IMMORTALIZED CELL LINE MARKET FOR INACTIVATION OF TUMOUR SUPPRESSION GENES, BY REGION 2020–2027 (USD MILLION)	40
TABLE 9 GLOBAL IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION)	42
TABLE 10 GLOBAL IMMORTALIZED CELL LINE MARKET FOR DIAGNOSTICS, BY REGION 2020–2027 (USD MILLION)	43
TABLE 11 GLOBAL IMMORTALIZED CELL LINE MARKET FOR DRUG DISCOVERY, BY REGION 2020–2027 (USD MILLION)	43
TABLE 12 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VACCINE PRODUCTION, BY REGION 2020–2027 (USD MILLION)	44
TABLE 13 GLOBAL IMMORTALIZED CELL LINE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION 2020–2027 (USD MILLION)	45
TABLE 14 GLOBAL IMMORTALIZED CELL LINE MARKET, BY END-USERS 2020–2027 (USD MILLION)	47
TABLE 15 GLOBAL IMMORTALIZED CELL LINE MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION 2020–2027 (USD MILLION)	48
TABLE 16 GLOBAL IMMORTALIZED CELL LINE MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION 2020–2027 (USD MILLION)	48
TABLE 17 GLOBAL IMMORTALIZED CELL LINE MARKET FOR RESEARCH LABORATORIES, BY REGION 2020–2027 (USD MILLION)	49
TABLE 18 GLOBAL IMMORTALIZED CELL LINE MARKET, BY REGION 2020–2027 (USD MILLION)	51
TABLE 19 GLOBAL IMMORTALIZED CELL LINE MARKET, BY REGION 2020 & 2027 (USD MILLION)	51
TABLE 20 AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2020–2027 (USD MILLION)	52
TABLE 21 AMERICAS IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION)	53
TABLE 22 AMERICAS IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	53
TABLE 23 AMERICAS IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION)	53
TABLE 24 AMERICAS IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION)	54
TABLE 25 AMERICAS IMMORTALIZED CELL LINE MARKET, BY END-USERS 2020–2027 (USD MILLION)	54
TABLE 26 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY COUNTRY 2020–2027 (USD MILLION)	54
TABLE 27 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION)	55
TABLE 28 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	55
TABLE 29 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION)	56
TABLE 30 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION)	56
TABLE 31 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY END-USER 2020–2027 (USD MILLION)	56
TABLE 32 US IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION)	57
TABLE 33 US IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	57
TABLE 34 US IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION)	57
TABLE 35 US IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION)	58
TABLE 36 US IMMORTALIZED CELL LINE MARKET, BY END-USER 2020–2027 (USD MILLION)	58
TABLE 37 CANADA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION)	58
TABLE 38 CANADA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	59
TABLE 39 CANADA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION)	59
TABLE 40 CANADA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION)	59
TABLE 41 CANADA IMMORTALIZED CELL LINE MARKET, BY END-USER 2020–2027 (USD MILLION)	60
TABLE 42 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION)	60
TABLE 43 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	60
TABLE 44 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION)	61
TABLE 45 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION)	61
TABLE 46 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY END-USER 2020–2027 (USD MILLION)	61
TABLE 47 EUROPE IMMORTALIZED CELL LINE MARKET, BY REGION 2020–2027 (USD MILLION)	62
TABLE 48 EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION)	63
TABLE 49 EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	63
TABLE 50 EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION)	63
TABLE 51 EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION)	64
TABLE 52 EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION)	64
TABLE 53 WESTERN EUROPE: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION)	65
TABLE 54 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION)	65
TABLE 55 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	66
TABLE 56 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION)	66
TABLE 57 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION)	66
TABLE 58 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION)	67
TABLE 59 GERMANY IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION)	67
TABLE 60 GERMANY IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION)	67

TABLE 61 GERMANY IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 68

TABLE 62 GERMANY IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 68

TABLE 63 GERMANY IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 68

TABLE 64 FRANCE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 69

TABLE 65 FRANCE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 66 FRANCE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 67 FRANCE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 70

TABLE 68 FRANCE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 70

TABLE 69 U.K IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 71

TABLE 70 U.K IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 71 U.K IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 72 U.K IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 72

TABLE 73 U.K IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 72

TABLE 74 ITALY IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 73

TABLE 75 ITALY IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 76 ITALY IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 77 ITALY IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 74

TABLE 78 ITALY IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 74

TABLE 79 SPAIN IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 75

TABLE 80 SPAIN IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 81 SPAIN IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 82 SPAIN IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 76

TABLE 83 SPAIN IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 76

TABLE 84 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 76

TABLE 85 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 86 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 87 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 77

TABLE 88 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 78

TABLE 89 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 78

TABLE 90 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 78

TABLE 91 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 79

TABLE 92 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 79

TABLE 93 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 79

TABLE 94 ASIA-PACIFIC: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80

TABLE 95 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 81

TABLE 96 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 97 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 98 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 82

TABLE 99 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 82

TABLE 100 JAPAN IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 82

TABLE 101 JAPAN IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 83

TABLE 102 JAPAN IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 83

TABLE 103 JAPAN IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 83

TABLE 104 JAPAN IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 84

TABLE 105 CHINA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 84

TABLE 106 CHINA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 84

TABLE 107 CHINA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 85

TABLE 108 CHINA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 85

TABLE 109 CHINA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 85

TABLE 110 INDIA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 86

TABLE 111 INDIA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 86

TABLE 112 INDIA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 86

TABLE 113 INDIA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 87

TABLE 114 INDIA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 87

TABLE 115 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 87

TABLE 116 SOUTH KOREA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 88

TABLE 117 SOUTH KOREA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 88

TABLE 118 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 88

TABLE 119 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 89

TABLE 120 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 89

TABLE 121 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE

2020–2027 (USD MILLION) 89
TABLE 122 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 90
TABLE 123 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 90
TABLE 124 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 90
TABLE 125 MIDDLE EAST AND AFRICA: IMMORTALIZED CELL LINE MARKET, BY REGION, 2020–2027 (USD MILLION) 91
TABLE 126 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 92
TABLE 127 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 92
TABLE 128 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 92
TABLE 129 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 93
TABLE 130 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 93
TABLE 131 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 93
TABLE 132 MIDDLE EAST IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 94
TABLE 133 MIDDLE EAST IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 94
TABLE 134 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 94
TABLE 135 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 95
TABLE 136 AFRICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 95
TABLE 137 AFRICA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 95
TABLE 138 AFRICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 96
TABLE 139 AFRICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 96
TABLE 140 AFRICA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 96
TABLE 141 GLOBAL IMMORTALIZED CELL LINE MARKET: KEY DEVELOPMENTS 100
15 List of Figures
FIGURE 1 GLOBAL IMMORTALIZED CELL LINE MARKET: MARKET STRUCTURE 20
FIGURE 2 RESEARCH PROCESS OF MRFR 22
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 25
FIGURE 4 PORTERS FIVE FORCES ANALYSIS OF GLOBAL IMMORTALIZED CELL LINE MARKET 32
FIGURE 5 SUPPLY CHAIN: GLOBAL IMMORTALIZED CELL LINE MARKET 33
FIGURE 6 GLOBAL IMMORTALIZED CELL LINE MARKET, BY METHOD 2020 & 2027 (USD MILLION) 36
FIGURE 7 GLOBAL IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020 & 2027 (USD MILLION) 42
FIGURE 8 GLOBAL IMMORTALIZED CELL LINE MARKET, BY END-USERS 2020 & 2027 (USD MILLION) 47
FIGURE 9 AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2020 (%) 52
FIGURE 10 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2020 (%) 55
FIGURE 11 EUROPE: IMMORTALIZED CELL LINE MARKET SHARE, BY REGION, 2020 (% SHARE) 62
FIGURE 12 WESTERN EUROPE: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2020 (%) 65
FIGURE 13 ASIA PACIFIC: IMMORTALIZED CELL LINE MARKET SHARE, BY COUNTRY, 2020 (%) 80
FIGURE 14 THE MIDDLE EAST AND AFRICA: IMMORTALIZED CELL LINE MARKET SHARE, BY REGION, 2020 (%) 91
FIGURE 15 GLOBAL IMMORTALIZED CELL LINE MARKET, MARKET SHARE ANALYSIS 2020 (%) 98
FIGURE 16 GLOBAL IMMORTALIZED CELL LINE MARKET COMPETITIVE LANDSCAPE (%) 99